These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7578423)

  • 1. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy.
    Griffin RJ; Curtin NJ; Newell DR; Golding BT; Durkacz BW; Calvert AH
    Biochimie; 1995; 77(6):408-22. PubMed ID: 7578423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP inhibitors for cancer therapy.
    Curtin NJ
    Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
    Lupo B; Trusolino L
    Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly (ADP-ribose) polymerase inhibitors in cancer treatment.
    Mason KA; Raju U; Buchholz TA; Wang L; Milas ZL; Milas L
    Am J Clin Oncol; 2014 Feb; 37(1):90-100. PubMed ID: 22495455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP inhibitor development for systemic cancer targeting.
    Zaremba T; Curtin NJ
    Anticancer Agents Med Chem; 2007 Sep; 7(5):515-23. PubMed ID: 17896912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
    Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PARP inhibitors: significant progress in cancer therapy].
    Dantzer F; Noel G; Schreiber V
    Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
    Sandhu SK; Yap TA; de Bono JS
    Eur J Cancer; 2010 Jan; 46(1):9-20. PubMed ID: 19926276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
    Dulaney C; Marcrom S; Stanley J; Yang ES
    Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting poly (ADP) ribose polymerase I (PARP-1) and PARP-1 interacting proteins for cancer treatment.
    Sakamoto-Hojo ET; Balajee AS
    Anticancer Agents Med Chem; 2008 May; 8(4):402-16. PubMed ID: 18473725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-ribose) polymerase-1 protects excessive DNA strand breaks from deterioration during repair in human cell extracts.
    Parsons JL; Dianova II; Allinson SL; Dianov GL
    FEBS J; 2005 Apr; 272(8):2012-21. PubMed ID: 15819892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly(ADP-ribosyl)ation inhibitors: promising drug candidates for a wide variety of pathophysiologic conditions.
    Beneke S; Diefenbach J; Bürkle A
    Int J Cancer; 2004 Oct; 111(6):813-8. PubMed ID: 15300792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase.
    White AW; Almassy R; Calvert AH; Curtin NJ; Griffin RJ; Hostomsky Z; Maegley K; Newell DR; Srinivasan S; Golding BT
    J Med Chem; 2000 Nov; 43(22):4084-97. PubMed ID: 11063605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP-1 inhibitors: a novel genetically specific agents for cancer therapy.
    Cipak L; Jantova S
    Neoplasma; 2010; 57(5):401-5. PubMed ID: 20568893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy.
    Haince JF; Rouleau M; Hendzel MJ; Masson JY; Poirier GG
    Trends Mol Med; 2005 Oct; 11(10):456-63. PubMed ID: 16154385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis.
    Tong WM; Cortes U; Wang ZQ
    Biochim Biophys Acta; 2001 Nov; 1552(1):27-37. PubMed ID: 11781113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
    Wang YQ; Wang PY; Wang YT; Yang GF; Zhang A; Miao ZH
    J Med Chem; 2016 Nov; 59(21):9575-9598. PubMed ID: 27416328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulfur and nitrogen mustards induce characteristic poly(ADP-ribosyl)ation responses in HaCaT keratinocytes with distinctive cellular consequences.
    Mangerich A; Debiak M; Birtel M; Ponath V; Balszuweit F; Lex K; Martello R; Burckhardt-Boer W; Strobelt R; Siegert M; Thiermann H; Steinritz D; Schmidt A; Bürkle A
    Toxicol Lett; 2016 Feb; 244():56-71. PubMed ID: 26383629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.